<DOC>
	<DOCNO>NCT01384383</DOCNO>
	<brief_summary>This Phase 2 , randomize , open-label exploratory study examine antiviral efficacy , safety , tolerability Response guide treatment ( RGT ) GS-5885 + GS-9451 + PEG/RBV ( 6 12 week ) , Peginterferon Alfa 2a ( PEG ) /Ribavirin ( RBV ) alone ( 24 week ) treatment naïve subject chronic Hep C ( HCV ) infection genotype ( GT ) 1 IL28B CC genotype .</brief_summary>
	<brief_title>GS-5885 , GS-9451 With Peginterferon Alfa 2a ( PEG ) Ribavirin Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection IL28B CC Genotype</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Males female 1870 year age Chronic HCV infection Subjects must liver biopsy result ( ≤ 3 year prior screen ) indicate absence cirrhosis . Alternatively noninvasive alternative liver biopsy ( FibroTest , FibroScan , Acoustic Radiation Force Impulse image ) within 6 month Screening country allow Monoinfection HCV genotype 1a 1b HCV RNA &gt; 10^4 IU/mL Screening IL28B CC genotype HCV treatment naïve Candidate PEG/RBV therapy Body mass index ( BMI ) 18 36 kg/m2 Creatinine clearance &gt; = 50 mL/min Agree use two form highly effective contraception method duration study 7 month last dose study medication . Females childbearing potential must negative pregnancy test Screening Baseline Exceed define threshold key laboratory parameter Screening Diagnosis autoimmune disease , decompensated liver disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , HIV , hepatitis B virus ( HBV ) , hepatocellular carcinoma malignancy ( exception certain skin cancer ) , hemoglobinopathy , retinal disease , immunosuppressed Subjects current use amphetamine , cocaine , opiate ( e.g. , morphine , heroin ) , ongoing alcohol abuse exclude . Subjects stable methadone maintenance treatment least 6 month prior Screening may include study Use prohibit concomitant medication two week prior baseline end treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>IL28B CC Genotype</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Peginterferon α-2a ( PEG )</keyword>
	<keyword>Genotype 1a/b</keyword>
	<keyword>GS 9451</keyword>
	<keyword>GS 5885</keyword>
	<keyword>Ribavirin ( RBV )</keyword>
	<keyword>HCV NS5A inhibitor</keyword>
	<keyword>HCV NS3 protease inhibitor</keyword>
</DOC>